The Fc Receptor Polymorphisms and Expression of Neutrophil Activation Markers in Patients with Sickle Cell Disease from Western India

Table 2

Hematological parameters among sickle cell disease patients and normal.

	HbS-homozygous; (127)	HbS-𝛽-thalassemia; (58)	Total; (185)	Normals; (75)	^∗𝑃 Value; (Total patients versus normals)
WBC * 10^3/mL	12.11±7.93	11.20±6.25	11.82±7.43	6.64±1.46	< 0.001
RBC * 10^6/mL	3.25±0.96	3.89±0.98	3.46±1.01	5.00±0.49	< 0.0001
HB (g/dL)	8.46±2.20	8.5±2.01	8.47±2.14	14.62±1.63	< 0.0001
HCT (%)	25.68±6.45	26.7±5.95	25.99±6.29	42.86±3.91	< 0.0001
MCV (fL)	79.93±12.09	69.27±7.67	76.48±11.92	85.86±7.42	< 0.0001
MCH (pg)	26.58±4.22	22.06±2.52	25.12±4.31	29.31±3.28	< 0.0001
MCHC (g/dL)	32.91±2.01	32.91±8.63	32.91±5.34	33.48±3.41	0.39
RDW (%)	20.41±4.58	22.29±4.45	21.02±4.61	14.11±1.23	< 0.0001
PLT * 10^3/mL	321.68±174.49	296.89±142.09	313.67±164.8	269.42±53.96	0.02
HbA2 (%)	3.05±0.79	5.09±0.96	3.71±1.27	2.79±0.28	< 0.0001
HbF (%)	18.97±9.5	19.14±8.33	19.02±9.12	0.30±0.36	< 0.0001
HbS (%)	72.06±10.12	68.21±9.29	70.81±9.99

∗Student’s 𝑡 test analysis comparing hematological parameters among patients and normal.